These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 29400013)

  • 1. Seromucinous component in endometrioid endometrial carcinoma as a histological predictor of prognosis.
    Miyamoto M; Takano M; Aoyama T; Soyama H; Yoshikawa T; Tsuda H; Furuya K
    J Gynecol Oncol; 2018 Mar; 29(2):e20. PubMed ID: 29400013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Morphologic Reproducibility, Genotyping, and Immunohistochemical Profiling Do Not Support a Category of Seromucinous Carcinoma of the Ovary.
    Rambau PF; McIntyre JB; Taylor J; Lee S; Ogilvie T; Sienko A; Morris D; Duggan MA; McCluggage WG; Köbel M
    Am J Surg Pathol; 2017 May; 41(5):685-695. PubMed ID: 28125452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53, estrogen and progesterone receptors in diagnostic curettage for endometrial adenocarcinoma and their correlation with morphological data and disease stage at hysterectomy.
    Bonfitto VL; de Angelo Andrade LA
    Sao Paulo Med J; 2003 Jul; 121(4):163-6. PubMed ID: 14595509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ovarian seromucinous carcinoma: report of a series of a newly categorized and uncommon neoplasm.
    Taylor J; McCluggage WG
    Am J Surg Pathol; 2015 Jul; 39(7):983-92. PubMed ID: 25723110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma.
    Soslow RA; Wethington SL; Cesari M; Chiappetta D; Olvera N; Shia J; Levine DA
    Am J Surg Pathol; 2012 Dec; 36(12):1771-81. PubMed ID: 23154767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. L1CAM expression associates with poor outcome in endometrioid, but not in clear cell ovarian carcinoma.
    Soovares P; Pasanen A; Bützow R; Lassus H
    Gynecol Oncol; 2017 Sep; 146(3):615-622. PubMed ID: 28625395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ovarian seromucinous carcinoma: an independent epithelial ovarian cancer?
    Hu Y; Fu K; Liu H; He Q; Qiu X; Yang W; Zhang Y
    J Ovarian Res; 2023 Jan; 16(1):18. PubMed ID: 36670456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sertoliform endometrioid carcinomas of the ovary: a clinicopathologic and immunohistochemical study of 13 cases.
    Ordi J; Schammel DP; Rasekh L; Tavassoli FA
    Mod Pathol; 1999 Oct; 12(10):933-40. PubMed ID: 10530556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The value of Cdx2 immunostaining in differentiating primary ovarian carcinomas from colonic carcinomas metastatic to the ovaries.
    Groisman GM; Meir A; Sabo E
    Int J Gynecol Pathol; 2004 Jan; 23(1):52-7. PubMed ID: 14668551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognosis of stage IA synchronous endometrial endometrioid and ovarian carcinomas.
    Zhan X; Li L; Wu M; Lang J
    Arch Gynecol Obstet; 2019 Oct; 300(4):1045-1052. PubMed ID: 31520260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mixed endometrial carcinomas with a "low-grade serous"-like component: a clinicopathologic, immunohistochemical, and molecular genetic study.
    Espinosa I; D'Angelo E; Corominas M; Gonzalez A; Prat J
    Hum Pathol; 2018 Jan; 71():65-73. PubMed ID: 29079180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Synchronous primary cancers of the endometrium and ovary: review of 43 cases].
    Ma SK; Zhang HT; Sun YC; Wu LY
    Zhonghua Zhong Liu Za Zhi; 2008 Sep; 30(9):690-4. PubMed ID: 19173912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinicopathologic study of seromucinous carcinoma of ovary].
    Tang SX; Sun YH; Xu Y; Zhou XR; Yang WT
    Zhonghua Bing Li Xue Za Zhi; 2016 Nov; 45(11):774-779. PubMed ID: 27821232
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunoexpression of the PTEN protein and matrix metalloproteinase-2 in endometrial cysts, endometrioid and clear cell ovarian cancer.
    Brucka A; Szyłło K
    Ginekol Pol; 2013 May; 84(5):344-51. PubMed ID: 23819399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Seromucinous ovarian tumor A comparison with the rest of ovarian epithelial tumors.
    Karpathiou G; Chauleur C; Corsini T; Venet M; Habougit C; Honeyman F; Forest F; Peoc'h M
    Ann Diagn Pathol; 2017 Apr; 27():28-33. PubMed ID: 28325358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Undifferentiated Carcinoma of the Endometrium: An Expanded Immunohistochemical Analysis Including PAX-8 and Basal-Like Carcinoma Surrogate Markers.
    Ramalingam P; Masand RP; Euscher ED; Malpica A
    Int J Gynecol Pathol; 2016 Sep; 35(5):410-8. PubMed ID: 26598976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma.
    Fukuda K; Mori M; Uchiyama M; Iwai K; Iwasaka T; Sugimori H
    Gynecol Oncol; 1998 Jun; 69(3):220-5. PubMed ID: 9648591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ovarian endometrioid tumors with yolk sac tumor component, an unusual form of ovarian neoplasm. Analysis of six cases.
    Nogales FF; Bergeron C; Carvia RE; Alvaro T; Fulwood HR
    Am J Surg Pathol; 1996 Sep; 20(9):1056-66. PubMed ID: 8764742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinicopathologic and survival analysis of synchronous primary endometrial and ovarian cancer].
    Wang Y; Yu M; Yang JX; Cao DY; Zhang Y; Shen K; You Y
    Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):816-822. PubMed ID: 30585019
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinicopathologic Features and the Loss of ARID1A Expression in Ovarian Seromucinous Borderline Tumors and Seromucinous Carcinomas.
    Ok Atılgan A; Özen Ö; Haberal Reyhan AN; Ayhan A
    Int J Surg Pathol; 2023 Jun; 31(4):398-408. PubMed ID: 36452965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.